In our quest to bring innovative treatment options to patients living with rare diseases, Pfizer is working with OPKO Health Inc. to develop and commercialize somatrogon, a potential treatment option for pre-pubertal children with growth hormone deficiency (GHD). GHD is a rare disease that affects one in approximately 4,000 to 10,000 people. Without treatment, those living with this condition will have persistent growth attenuation, a very short height in adulthood and may experience other health problems. We are encouraged by initialtop-line results from a recently completed Phase 3 study comparing somatrogon, dosed once-weekly to daily growth hormone, and the possibility of reducing the burden of once-daily treatment on children with GHD and their caregivers, while potentially also increasing treatment adherence.